1
Alexander Levitzki, Chaim Gilon, Michael Chorev, Aviv Gazit: Styryl compounds which inhibit EGF receptor protein tyrosine kinase. Yissum Research Development Company of the Hebrew University of Jerusalem, Synnestvedt & Lechner, June 8, 1993: US05217999 (132 worldwide citation)

A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is a ...


2
Alfred P Spada, Paul E Persons, Alexander Levitzki, Chaim Gilon: Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Synnestvedt & Lechner, April 12, 1994: US05302606 (120 worldwide citation)

Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound optionally subs ...


3
Harald App, Gerald M McMahon, Peng Cho Tang, Aviv Gazit, Alexander Levitzki: Quinazoline compounds and compositions thereof for the treatment of disease. Sugen, Yissum Research Development Co of the Hebrew University of Jerusalem, Pennie & Edmonds, August 11, 1998: US05792771 (56 worldwide citation)

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FL ...


4
Harald App, Gerald M McMahon, Peng Cho Tang, Aviv Gazit, Alexander Levitzki: Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis. Yissum Research Development, Sugen, Pennie & Edmonds, January 27, 1998: US05712395 (53 worldwide citation)

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FL ...


5
Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Laura K Shawver, Jianming Tsai, Peng Cho Tang: Methods and compositions for inhibiting cell proliferative disorders. Sugen, Yissum Research and Development Company of the Hebrew University of Jerusalem, Lyon & Lyon, June 30, 1998: US05773476 (49 worldwide citation)

The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.


6
Harald App, Gerald M McMahon, Peng Cho Tang, Aviv Gazit, Alexander Levitzki: Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis. Sugen, Yissum Research Development, Pennie & Edmonds, June 9, 1998: US05763441 (39 worldwide citation)

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FL ...


7
Eyal Mishani, Iris Ben David, Yulia Rozen, Gluseppina Ortu, Alexander Levitzki: Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy. Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development, G E Ehrlich, May 13, 2003: US06562319 (35 worldwide citation)

Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are di ...


8
Alexander Levitzki, Chaim Gilon, Aviv Gazit: Certain indole compounds which inhibit EGF receptor tyrosine kinase. Yissum Research Development Company of the Hebrew University of Jerusalem, Synnestvedt & Lechner, March 23, 1993: US05196446 (34 worldwide citation)

Heteroarylethenediyl compounds wherein the heteroaryl group can be mono- or icyclic heteroaryl and the aryl group can be or mono- or bicyclic carbocyclic, said compound optionally substituted or polysubstituted, with the proviso that the heteroaryl group is not furyl or thienyl when the ethenediyl g ...


9
Harald App, Gerald M McMahon, Peng Cho Tang, Aviv Gazit, Alexander Levitzki: Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease. Yissum Research Development Company of the Hebrew University of Jerusalem, Sugen, Pennie & Edmonds, November 9, 1999: US05981569 (29 worldwide citation)

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FL ...


10
Alexander Levitzki, Aviv Gazit, Shmuel Banai, S David Gertz, Gershon Golomb: PDGF receptor kinase inhibitory compounds their preparation and compositions. Yissum Research and Development Company of the Hebrew University of Jerusalem, Mark M Friedman, August 3, 1999: US05932580 (29 worldwide citation)

PDGF receptor kinase inhibitory compounds of the quinoxaline family, methods for their synthesis and containment is slow release pharmaceutical preparations, and their use for treatment of proliferative malignant and non-malignant diseases or disorders by local or systemic application. A compound ac ...